Pan-immune-inflammation value could be a new marker to differentiate between vascular Behçet’s disease and non-vascular Behçet’s disease
T. Ocak, N. Lermı, Z. Yılmaz Bozkurt, B. Yagız, B.N. Coskun, E. Dalkılıc, Y. Pehlıvan Division of Rheumatology, Faculty of Medicine, Uludag University, Bursa, Turkey. tugba@uludag.edu.tr
OBJECTIVE: Behçet’s disease etiology is uncertain, and no specific diagnostic markers exist in the laboratory. This retrospective study aimed to evaluate the role of inflammatory and hematological parameters, mainly Pan-Immune-Inflammation-Value (PIV), in predicting vascular Behçet’s disease (VBD).
PATIENTS AND METHODS: A total of 85 patients with VBD and 92 patients without vascular involvement (non-VBD) were included in this study. Neutrophil, monocyte, platelet, and lymphocyte subsets are all included in the PIV, a new blood-based biomarker.
RESULTS: The optimal cut-off values for the PIV were determined to be ≥261.6. White blood cell, neutrophil, monocyte, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration (MCHC), red cell distribution, platelet, plateletcrit, PIV, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, sedimentation, c-reactive protein (CRP) values were significantly associated with VBD in univariate analysis. After multivariate analysis, PIV [odds ratio (OR): 2.758; 95% confidence interval (CI): 1.327-5.736; p=0.007] and CRP (OR: 4.029; 95% CI: 1.924-8.438; p<0.001) were found to be a positive predictor for VBD, while MCHC (OR: 0.722; 95% CI: 0.530-0.983; p=0.039) was seen as a negative predictor.
CONCLUSIONS: Based on our results, PIV, an easily accessible, cost-effective, and new composite biomarker, has a significant predictive value in VBD.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
T. Ocak, N. Lermı, Z. Yılmaz Bozkurt, B. Yagız, B.N. Coskun, E. Dalkılıc, Y. Pehlıvan
Pan-immune-inflammation value could be a new marker to differentiate between vascular Behçet’s disease and non-vascular Behçet’s disease
Eur Rev Med Pharmacol Sci
Year: 2024
Vol. 28 - N. 5
Pages: 1751-1759
DOI: 10.26355/eurrev_202403_35588